Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315707091> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W4315707091 endingPage "e444" @default.
- W4315707091 startingPage "e443" @default.
- W4315707091 abstract "Objectives: The prevalence of peripheral artery disease (PAD) is high in hemodialysis patients and has a poor prognosis. More than 10,000 hemodialysis patients require lower-extremity amputation. LDL-apheresis has been initiated as a supportive treatment for patients with chronic limb-threatening ischemia (CLTI), especially in cases where revascularization by endovascular therapy (EVT) is not sufficiently effective. In 2021, a new adsorption-type blood purification device, Rheocana, that can selectively remove LDL-C and fibrinogen, was developed. In a clinical trial, 45.9% of the ulcers were healed using Rheocana. Since then, it has been widely used for dialysis patients with CLTI in Japan; however, hypotension during LDL-apheresis is still a major adverse event. Design and Methods: Case report. Results: An 83-year-old Japanese man presented with a right leg ulcer. He had started undergoing hemodialysis 3 years prior because of diabetic kidney disease. CLTI was recognized 6 months prior, and repeated EVT was ineffective and failed to improve the ulcer. His blood pressure was 129/71 mmHg and antihypertensive agents were not used. LDL-apheresis with Rheocana was initiated; however, his systolic blood pressure decreased to 60 mmHg, and LDL-apheresis was stopped immediately. After discontinuing LDL-apheresis, the his blood pressure recovered. Anticoagulants were changed from heparin to nafamostat mesylate, and LDL-apheresis was restarted. His blood pressure did not decrease after anticoagulation therapy, and his leg ulcer was successfully healed. Conclusion: During LDL-apheresis, factor VIII and kallikrein are activated when the plasma comes in contact with the negatively charged dextran surface, resulting in a decrease in blood pressure by promoting bradykinin production. And thus, in case of ACEI use is contraindicated. Nafamostat mesylate is thought to reduce bradykinin production by suppressing kallikrein. Blood pressure often decreases by approximately 30 mmHg when LDL-apheresis is started; however, nafamostat mesylate was dramatically effective in preventing decrease in blood pressure. Nafamostat mesylate should be used in patients with CLTI and low blood pressure." @default.
- W4315707091 created "2023-01-12" @default.
- W4315707091 creator A5005631544 @default.
- W4315707091 creator A5007843034 @default.
- W4315707091 creator A5055647978 @default.
- W4315707091 creator A5065050858 @default.
- W4315707091 creator A5073763837 @default.
- W4315707091 creator A5080362733 @default.
- W4315707091 date "2023-01-01" @default.
- W4315707091 modified "2023-10-03" @default.
- W4315707091 title "PS-R05-4: PREVENTION OF HYPOTENSION DURING LDL-APHERESIS BY NAFAMOSTAT MESYLATE: A CASE REPORT" @default.
- W4315707091 doi "https://doi.org/10.1097/01.hjh.0000917388.14423.b2" @default.
- W4315707091 hasPublicationYear "2023" @default.
- W4315707091 type Work @default.
- W4315707091 citedByCount "0" @default.
- W4315707091 crossrefType "journal-article" @default.
- W4315707091 hasAuthorship W4315707091A5005631544 @default.
- W4315707091 hasAuthorship W4315707091A5007843034 @default.
- W4315707091 hasAuthorship W4315707091A5055647978 @default.
- W4315707091 hasAuthorship W4315707091A5065050858 @default.
- W4315707091 hasAuthorship W4315707091A5073763837 @default.
- W4315707091 hasAuthorship W4315707091A5080362733 @default.
- W4315707091 hasBestOaLocation W43157070911 @default.
- W4315707091 hasConcept C126322002 @default.
- W4315707091 hasConcept C141071460 @default.
- W4315707091 hasConcept C2776738589 @default.
- W4315707091 hasConcept C2778063415 @default.
- W4315707091 hasConcept C2778751355 @default.
- W4315707091 hasConcept C2779978075 @default.
- W4315707091 hasConcept C42219234 @default.
- W4315707091 hasConcept C71924100 @default.
- W4315707091 hasConcept C84393581 @default.
- W4315707091 hasConcept C89560881 @default.
- W4315707091 hasConcept C90924648 @default.
- W4315707091 hasConceptScore W4315707091C126322002 @default.
- W4315707091 hasConceptScore W4315707091C141071460 @default.
- W4315707091 hasConceptScore W4315707091C2776738589 @default.
- W4315707091 hasConceptScore W4315707091C2778063415 @default.
- W4315707091 hasConceptScore W4315707091C2778751355 @default.
- W4315707091 hasConceptScore W4315707091C2779978075 @default.
- W4315707091 hasConceptScore W4315707091C42219234 @default.
- W4315707091 hasConceptScore W4315707091C71924100 @default.
- W4315707091 hasConceptScore W4315707091C84393581 @default.
- W4315707091 hasConceptScore W4315707091C89560881 @default.
- W4315707091 hasConceptScore W4315707091C90924648 @default.
- W4315707091 hasIssue "Suppl 1" @default.
- W4315707091 hasLocation W43157070911 @default.
- W4315707091 hasLocation W43157070912 @default.
- W4315707091 hasOpenAccess W4315707091 @default.
- W4315707091 hasPrimaryLocation W43157070911 @default.
- W4315707091 hasRelatedWork W113810927 @default.
- W4315707091 hasRelatedWork W1968752703 @default.
- W4315707091 hasRelatedWork W1997915342 @default.
- W4315707091 hasRelatedWork W2003447000 @default.
- W4315707091 hasRelatedWork W2003938723 @default.
- W4315707091 hasRelatedWork W2025499134 @default.
- W4315707091 hasRelatedWork W2047967234 @default.
- W4315707091 hasRelatedWork W2439875401 @default.
- W4315707091 hasRelatedWork W40023729 @default.
- W4315707091 hasRelatedWork W2405416695 @default.
- W4315707091 hasVolume "41" @default.
- W4315707091 isParatext "false" @default.
- W4315707091 isRetracted "false" @default.
- W4315707091 workType "article" @default.